A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt

Trial Profile

A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2014

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Stroke; Thromboembolism; Thrombosis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms RE-ALIGN
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 01 Sep 2013 Data were presented at the 2013 European Society of Cardiology (ESC) congress and published in the New England Journal of Medicine, according to a Boehringer Ingelheim media release.
    • 26 Aug 2013 Results will be presented at the 2013 European Society of Cardiology Congress (ESC-2013) according to a Boehringer Ingelheim media release.
    • 01 Jun 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top